Victoza is an incretin mimetic drug that works by mimicking a natural hormone in the body that stimulates the production of insulin from the pancreas, medical experts say. While it offers promising therapeutic effects, the drug has also been linked to a string of serious side effects, including thyroid cancer, kidney failure and pancreatitis, which may bring about permanent disability, organ failure, and even death. These potentially fatal side effects have also been the center of a number of Victoza lawsuits lodged in courts throughout the United States, online publications say.
On March 14, 2013, Victoza, including other incretin mimetic drugs widely used in controlling type 2 diabetes, has drawn the scrutiny of the US Food and Drug Administration for its potential link to increased risk of pancreatitis and precancerous changes to the pancreas. Other similar medications that may also have the same adverse effect include Byetta, Januvia, Bydureon, Oseni, Kazano, Juvisync, Tradjenta, Kombiglyze XR, Nesina, Janumet XR and Onglyza. This is the first time that the agency looked into these drugs’ possible relation to pancreatitis or cancer precursors, and the agency reportedly wanted to further investigate this matter.
This is not the first time that the FDA warned the public about the risk associated with the use of incretin mimetic drugs, online sources say. In fact, the agency had previously alerted the public about reports of acute pancreatitis linked to Januvia and Byetta. The most recent study on Januvia and Byetta indicated that use of these drugs may double the risk of pancreatitis in patients. The FDA reportedly stated that it will continue to evaluate all available clinical data in order to further understand this potential safety issue. An advisory will also be released to the public when the agency lands additional findings or reaches final conclusions or recommendations, according to online news reports.
In the meantime, the FDA encourages both healthcare providers and patients to report any side effects or adverse events that may occur when using incretin mimetics. Researchers of the studies conducted on these drugs also urge patients not to stop taking the medication. In fact, even the American Association of Clinical Endocrinologists and the American Diabetes Association reportedly pointed out that patients should not change their treatment on the basis of research alone.
In their desire to provide added and up-to-date information regarding lawsuits involving Victoza as well as other issues involving the said drug, various personal injury law firms have put up their own respective online information hubs, similar to the Rottenstein Law Group’s www.rotlaw.com. These online sites have also become useful means to patients who wish to contact law firms about filing legal claims.
On March 14, 2013, Victoza, including other incretin mimetic drugs widely used in controlling type 2 diabetes, has drawn the scrutiny of the US Food and Drug Administration for its potential link to increased risk of pancreatitis and precancerous changes to the pancreas. Other similar medications that may also have the same adverse effect include Byetta, Januvia, Bydureon, Oseni, Kazano, Juvisync, Tradjenta, Kombiglyze XR, Nesina, Janumet XR and Onglyza. This is the first time that the agency looked into these drugs’ possible relation to pancreatitis or cancer precursors, and the agency reportedly wanted to further investigate this matter.
This is not the first time that the FDA warned the public about the risk associated with the use of incretin mimetic drugs, online sources say. In fact, the agency had previously alerted the public about reports of acute pancreatitis linked to Januvia and Byetta. The most recent study on Januvia and Byetta indicated that use of these drugs may double the risk of pancreatitis in patients. The FDA reportedly stated that it will continue to evaluate all available clinical data in order to further understand this potential safety issue. An advisory will also be released to the public when the agency lands additional findings or reaches final conclusions or recommendations, according to online news reports.
In the meantime, the FDA encourages both healthcare providers and patients to report any side effects or adverse events that may occur when using incretin mimetics. Researchers of the studies conducted on these drugs also urge patients not to stop taking the medication. In fact, even the American Association of Clinical Endocrinologists and the American Diabetes Association reportedly pointed out that patients should not change their treatment on the basis of research alone.
In their desire to provide added and up-to-date information regarding lawsuits involving Victoza as well as other issues involving the said drug, various personal injury law firms have put up their own respective online information hubs, similar to the Rottenstein Law Group’s www.rotlaw.com. These online sites have also become useful means to patients who wish to contact law firms about filing legal claims.
